Gain Therapeutics Inc. (GANX)
NASDAQ: GANX
· Real-Time Price · USD
1.80
-0.06 (-3.23%)
At close: May 15, 2025, 3:59 PM
1.85
2.78%
After-hours: May 15, 2025, 05:46 PM EDT
-3.23% (1D)
| Bid | 1.65 |
| Market Cap | 52.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -20.41M |
| EPS (ttm) | -0.89 |
| PE Ratio (ttm) | -2.02 |
| Forward PE | -2.15 |
| Analyst | Buy |
| Ask | 2.09 |
| Volume | 357,131 |
| Avg. Volume (20D) | 282,993 |
| Open | 1.85 |
| Previous Close | 1.86 |
| Day's Range | 1.74 - 1.89 |
| 52-Week Range | 0.89 - 3.19 |
| Beta | 0.17 |
About GANX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GANX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GANX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+14.68%
Gain Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
7 months ago
+17.03%
Gain Therapeutics shares are trading higher after the company announced the presentation of new evidence supporting the disease-modifying activity of Gt-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease.
